REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Neuro Performance Stack

Cognitive Enhancementintermediate

81

synergy

81
Share
Peptides

3

Avg Daily mcg

1,150

Level

intermediate

Added

May 17, 2026

Overview

The Neuro Performance Stack extends the classic Russian Brain Stack (Semax + Selank) with BPC-157, adding a gut-brain axis component and systemic healing support to the core cognitive and anxiolytic effects. This combination is particularly popular with high-performers dealing with both cognitive demands and physical stress. Semax and Selank provide the core cognitive effects: BDNF upregulation, focus, memory, and anxiolytic stability (see Russian Brain Stack for detailed mechanisms). BPC-157 adds a dimension that neither cognitive peptide addresses — the gut-brain connection. The gut-brain axis is increasingly recognized as a bidirectional communication system where GI health directly impacts cognitive function, mood, and stress resilience. BPC-157 heals the gut mucosal lining, reduces intestinal inflammation, and supports neurotransmitter production in the enteric nervous system. Users with gut dysfunction often find that cognitive peptides underperform until the gut component is addressed. Beyond gut-brain axis effects, BPC-157 has direct central nervous system activity. It modulates dopaminergic signaling, has demonstrated neuroprotective effects in animal models of brain injury, and supports peripheral nerve regeneration. In the context of this stack, BPC-157 provides a supportive background of neural tissue health that complements Semax''s acute BDNF upregulation. This stack is particularly well-suited for practitioners, executives, athletes, and high-performers who face both cognitive demands and physical stress — situations where the body''s healing capacity and cognitive performance are both taxed simultaneously.

Dosing Protocol

Semax

Every day· intranasal

Read more about Semax →

600 mcg

per dose

Selank

Every day· intranasal

Read more about Selank →

300 mcg

per dose

BPC-157

Every day· subcutaneous

Read more about BPC-157 →

250 mcg

per dose

Goals & Evidence

Cognitive performanceAnxiety reductionGut-brain healthNeural protectionStress resilience
Evidence tier:Animal Studies

Warnings

  • BPC-157 is currently FDA Category 2 — reclassification pending.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.